🧬 MET Cancer Research

MET is a receptor tyrosine kinase that plays a significant role in cell growth and survival, making it an important focus in cancer research, particularly for lung cancer patients. When MET becomes abnormally activated through mutations, amplifications, or overexpression, it can drive cancer cell proliferation and contribute to treatment resistance. Understanding MET as a biomarker has become crucial for oncologists and researchers developing more precise diagnostic approaches and targeted treatment strategies.

Researchers have identified MET alterations in a subset of lung cancer patients, which has opened new avenues for personalized medicine. By detecting MET changes through advanced diagnostic techniques, physicians can better stratify patients and select those who may benefit from MET-targeted therapies. This biomarker-driven approach represents a shift toward precision oncology, where treatments are matched to each patient's unique tumor characteristics. Current studies are exploring how MET testing can improve treatment selection, predict response to therapy, and help overcome resistance to other targeted drugs.

On this page, you'll find the latest peer-reviewed research articles examining MET as a biomarker in lung cancer diagnostics and treatment. These studies represent the current state of scientific investigation into how MET analysis can enhance patient outcomes and advance our understanding of cancer biology.